List view / Grid view

Biosimilars

Filter the results

 

article

Five patent issues that European biosimilar developers should consider before entering the US market

26 June 2020 | By , ,

As patents on originator biologic medicines begin to expire, there are growing opportunities for biosimilars to enter the market at lower prices. Joshua Whitehill, Natasha Daughtrey and Grace Truong discuss key aspects of US patent law that European developers should consider before entering the American market.